Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Bullboard Posts
Comment by pericles1on Sep 13, 2012 7:53pm
481 Views
Post# 20360400

RE: RE: We are in Limbo!

RE: RE: We are in Limbo!

You actually hit it on the head Singing it's all about Brad's explanations what weight should be given. I am like the market somewhat confused. I thought the questions in the conference call were the best I have ever heard in a call and I have been a shareholder for over eight years. The funny part is a couple analysts asked about timelines and Brad stating it should not affect us much will summit for approval in 2014, ya like December instead of January. His answer was the most bull in the entire call.

My take is that he has doubts about the study and when he saw the break down of the two groups it was a clear opportunity. Much higher chance of success with the mets group. Also if he study showed only a effective response in the mets group we would not be able to recruit the local recurrance in Phase II a greater delay.  I also see the possibility of another stock offering now before the results are known a definite negative for me. I am not buying or selling but need to think this information over and listen a couple more times to the conference call. It's a most unusual situation!

Bullboard Posts